RenovoRx, Inc. (NASDAQ:RNXT – Get Free Report) shares rose 2.5% during trading on Thursday . The stock traded as high as $1.09 and last traded at $1.03. Approximately 5,062 shares traded hands during mid-day trading, a decline of 89% from the average daily volume of 47,122 shares. The stock had previously closed at $1.01.
Wall Street Analysts Forecast Growth
Separately, Ascendiant Capital Markets boosted their price target on RenovoRx from $8.00 to $8.25 and gave the company a “buy” rating in a report on Thursday, September 12th.
Get Our Latest Research Report on RNXT
RenovoRx Stock Performance
RenovoRx (NASDAQ:RNXT – Get Free Report) last posted its earnings results on Tuesday, August 13th. The company reported ($0.10) EPS for the quarter.
RenovoRx Company Profile
RenovoRx, Inc, a clinical-stage biopharmaceutical company, focuses on developing proprietary targeted combination therapies to improve therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is RenovoGem, an oncology drug-device combination product, consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for the locally advanced pancreatic cancer.
Further Reading
- Five stocks we like better than RenovoRx
- Top Biotech Stocks: Exploring Innovation Opportunities
- When Is the Best Time to Invest in Mutual Funds?
- What is a Low P/E Ratio and What Does it Tell Investors?
- Is NVIDIA Stock in a Correction or Consolidation?
- Low PE Growth Stocks: Unlocking Investment Opportunities
- 3 Oversold Stocks with Big RSI Rebound Potential
Receive News & Ratings for RenovoRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RenovoRx and related companies with MarketBeat.com's FREE daily email newsletter.